RARE DISEASERESEARCH ATLAS

ORPHA:308393

Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B

high confidenceSubtype of disorder

Also known as: Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type B · MOCOD type B

Query health: suspect — Only one of 3 strategies returned hits (phrase).

Publications

15

32th percentile

Trials

0

Interventional, condition-specific

Researchers

122

Distinct authors in sample

Gene link

MOCS2

Definitive

Readiness

2/6

Stages with a signal

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

MOCODB · combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type B · molybdenum cofactor deficiency B · molybdenum cofactor deficiency, complementation group type B · sulfite oxidase deficiency due to molybdenum cofactor deficiency type B

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — MOCS2

  2. LiteraturePresent

    15 matched papers (14 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (MOCS2).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

15

15 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

15 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

14 in the last 10 years · high confidence · 32th percentile (publications denominator)

Phrase hits: 15 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

122

Distinct author names in 15 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Abdelhak S2 papers · 2024

    Biomedical Genomics and Oncogenetics Laboratory (LR16IPT05), Institut Pasteur de Tunis, Tunis, Tunisia.

    Papers in Europe PMC
  2. 02
    Chen S2 papers · 2021

    Department of Neonatology, The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.

    Papers in Europe PMC
  3. 03
    Chouchane L2 papers · 2024

    Department of Genetic Medicine, Weill Cornell Medicine, New York, NY, USA.

    Papers in Europe PMC
  4. 04
    Liu Y2 papers · 2023

    Department of Genetics, Jiangxi Maternal and Child Health Hospital, 330006, Nanchang, China.

    Papers in Europe PMC
  5. 05
    Mezzi N2 papers · 2024

    Biomedical Genomics and Oncogenetics Laboratory (LR16IPT05), Institut Pasteur de Tunis, Tunis, Tunisia.

    Papers in Europe PMC
  6. 06
    Romdhane L2 papers · 2024

    Biomedical Genomics and Oncogenetics Laboratory (LR16IPT05), Institut Pasteur de Tunis, Tunis, Tunisia. lilia.romdhane@fsb.rnu.tn.

    Papers in Europe PMC
  7. 07
    Shan J2 papers · 2024

    Department of Genetic Medicine, Weill Cornell Medicine, New York, NY, USA.

    Papers in Europe PMC
  8. 08
    Wang L2 papers · 2023

    BGI-Wuhan Clinical Laboratory, BGI-Shenzhen, 430074, Wuhan, China.

    Papers in Europe PMC
  9. 09
    Abassi N1 paper · 2024

    Genomics and Oncogenetics Laboratory (LR16IPT05), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia.

    Papers in Europe PMC
  10. 10
    Alharbi AM1 paper · 2022

    Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Hail, Saudi Arabia.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

Broader category sulfite oxidase deficiency due to molybdenum cofactor deficiency also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Broader category: sulfite oxidase deficiency due to molybdenum cofactor deficiency

0

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Parent-category matching found a broader label but no interventional trials under it. How we count trials.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B" OR "Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type B" OR "Combined deficiency of the sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type B" OR "MOCOD type B" OR "MOCODB" OR "molybdenum cofactor deficiency B" OR "molybdenum cofactor deficiency, complementation group type B"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Molybdenum Cofactor Deficiency, Complementation Group B

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B" OR "Combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type B" OR "Combined deficiency of the sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase type B" OR "MOCOD type B" OR "MOCODB" OR "molybdenum cofactor deficiency B" OR "molybdenum cofactor deficiency, complementation group type B" OR "Molybdenum Cofactor Deficiency, Complementation Group B" OR "MOCS2" OR "encephalopathy due to sulfite oxidase deficiency"

Recall-expansion terms: MOCS2, encephalopathy due to sulfite oxidase deficiency

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"sulfite oxidase deficiency due to molybdenum cofactor deficiency"

Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T12:51:44.862Z